retatrutide glp-1 gip glucagon receptor agonist (Eli Lilly's triple GLP-1/GIP/Glucagon agonist) just delivered the most impressive obesity + osteoarthritis data we've ever seen in the phase 3 TRIUMPH-4 trial: Retatrutide 50mg | High Potency

The results of phase 2 (dose-ranging) trials with primary endpoints of HbA 1c change (Rosenstock et al, 2023) and body-weight change (Jastreboff et al, 2023) are shown in Table 6

Research-grade peptides undergo rigorous quality control measures

The glucagon arm is what distinguishes it from every GLP-1 and dual-agonist compound it increases energy expenditure in addition to the appetite and glycemic effects of the incretin receptors ( Coskun et al., Cell Metab 2022 )

It works the same way mechanistically, activating the GLP-1 receptor to reduce appetite, slow gastric emptying and improve insulin sensitivity, but the small molecule structure means it can be taken orally with fewer absorption constraints. In trials, orforglipron lowered blood sugar and produced meaningful weight loss in people with obesity and in those with type 2 diabetes, says LaValle